Company Overview and News
2018-09-14 seekingalpha - 1
REITs are unique in terms of their ability to grow moats; there are essentially two valuable levers that the company can (and should) utilize to build competitive advantage.
JCP DCT OPRF PSA.A CVS SHLD AMT EQY PSB ROST PSA EQIT WPC DRE KDNUU SBRA PSAXZ CCP VTR PPS COST O KND PLD
Greetings, and welcome to Regency Centers’ Second Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
REG EQIT EQY
TEL-AVIV, Israel, July 26, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced that on July 25, 2018, wholly-owned subsidiaries of the Company sold 5.6 million shares of common stock of Regency Centers Corporation (NYSE:REG) (“Regency”), for approximately $61.
REG FCR.DB.H FCR.DB.I FCR.DB.J GZT DTK EQIT FCRGF GZT FCR FCR.DB.E EQY
Good afternoon, and welcome to DDR Reports Second Quarter 2018 Operating Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
DDR BGFLX DDR.WI EQIT EQY
Regency Centers Corporation’s (REG - Free Report) focus on building a premium portfolio of grocery-anchored shopping centers, aimed at driving dependable traffic, bodes well. However, the company’s growing development and redevelopment pipeline exposes it to various risks such as rising construction costs, entitlement delays and lease-ups.
REG LB TCO EQIT MU KIM MAC EQY
Ladies and gentlemen, thank you for standing by. Welcome to the Gazit-Globe First Quarter 2018 Results Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by question-and-answer session. I advise you that this conference is being recorded today, Tuesday, May 29, 2018. The presentation that will be used in today's call and the financial statements can be found on Gazit-Globe's Web site at www.
FCAP URBN EQIT EQY
Given the turbulence, I decided my time was better spent searching for new ideas and that, as a recently launched long-biased fund, the letter should address the selloff.
DDR TLSTF EQIT EQY
At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
REG EQIT EQY
Regency Centers Corporation’s (REG - Free Report) first-quarter 2018 funds from operations (FFO) per share of 96 cents surpassed the Zacks Consensus Estimate of 94 cents. Further, results compared favorably with 27 cents reported in the year-ago quarter. However, results in the year-ago period included one-time merger-related costs of 55 cents per share. The company’s quarterly results reflect growth in same-property net operating income (NOI).
REG LRCX TWX PF TWC EQIT FRT ESS HST EQY
Regency Centers Corp. (REG - Free Report) is slated to report first-quarter 2018 results on Apr 30, after the market closes. Both its revenues and funds from operations (FFO) per share are expected to experience year-over-year growth. Last quarter, this Jacksonville, FL-based retail real estate investment trust (REIT) delivered in-line FFO per share. Results reflected growth in same-property net operating income (NOI) and strong leasing activity during the quarter.
REG TCO EQIT SPG MS RLJ EQY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...